Search clinical trials for: aleglitazar

Total 23 results

Hoffmann-La Roche

Completed

A Study of The Effect of Hepatic Impairment on The Pharmacokinetics of Aleglitazar

Healthy Volunteer

United States
Hoffmann-La Roche

Completed

A Pharmacokinetic Study of Aleglitazar in Healthy Chinese Volunteers

Healthy Volunteer

China
Hoffmann-La Roche

Completed

A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities

Cardiovascular Disease, Diabetes Mellitus Type 2

Germany, Spain, Korea, Republic of, United States, Colombia, Mexico, Hungary, Canada, Austria, Estonia, Malaysia, Australia, Poland, Thailand, Czech Republic, Latvia, Italy, Romania, Russian Federation, Chile, Lithuania, Sweden, United... and more
Hoffmann-La Roche

Withdrawn

A Study of Alegitazar in Patients With Type 2 Diabetes And Chronic Kidney Disease (Alerenal Study)

Diabetes Mellitus Type 2, Kidney Disease, Chronic
Hoffmann-La Roche

Completed

A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus

Diabetes Mellitus Type 2

Australia, France, Spain, Sweden, China, Korea, Republic of, United States, Canada, Germany, Ireland, Mexico, Poland, India, Denmark, Hungary, United Kingdom, New Zealand, Malaysia, Netherlands, Russian Federation, Thailand, Romania, Ita... and more
Hoffmann-La Roche

Completed

A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Sulfonylurea Alone or Sulfonylurea Plus Metformin Therapy

Diabetes Mellitus Type 2

Colombia, United States, Mexico, Guatemala, Argentina
Hoffmann-La Roche

Completed

A Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus Who Have Not Previously Received Anti-Hyperglycemic Therapy

Diabetes Mellitus Type 2

United States, Mexico
Hoffmann-La Roche

Completed

A Comparative Study of Aleglitazar and Actos in Patients With Type 2 Diabetes Mellitus and New York Heart Association (NYHA) Class II Heart Failure.

Diabetes Mellitus Type 2

United States, Russian Federation, Israel, Mexico, Ukraine, Romania
Hoffmann-La Roche

Completed

A Study of Aleglitazar in Monotherapy in Patients With Type 2 Diabetes Mellitus Who Are Drug-Naïve to Anti-Hyperglycemic Therapy

Diabetes Mellitus Type 2

Hong Kong, China, Malaysia
Hoffmann-La Roche

Completed

A Study to Evaluate the Effect of Aleglitazar on Cardiac Energetics and Function in Patients With Type 2 Diabetes Mellitus and no History of Coronary Artery Disease

Diabetes Mellitus Type 2

United Kingdom
Hoffmann-La Roche

Completed

A Comparison of the Effects of Aleglitazar and Actos on Renal Function on Patients With Type 2 Diabetes.

Diabetes Mellitus Type 2

United States, Russian Federation, Mexico, Ukraine, Puerto Rico
Hoffmann-La Roche

Completed

A Study of Aleglitazar in Patients With Type 2 Diabetes

Diabetes Mellitus Type 2

Italy, Hong Kong, Romania, Greece, United States, Mexico, Serbia, Russian Federation
Hoffmann-La Roche

Completed

A Study of Aleglitazar in Type 2 Diabetes Patients With Moderate Renal Impairment

Diabetes Mellitus Type 2

Australia, Hong Kong, Colombia, Russian Federation, Germany, Hungary, Italy, Mexico, Peru, Romania, Slovakia, Brazil, El Salvador
Hoffmann-La Roche

Completed

A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Monotherapy

Diabetes Mellitus Type 2

Korea, Republic of, China
Hoffmann-La Roche

Completed

A Study of The Effect of Aleglitazar on Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin

Diabetes Mellitus Type 2

Germany
Eli Lilly and Company

Completed

An Evaluation of an Oral Antidiabetic Agent for the Treatment of Type 2 Diabetes

Diabetes Mellitus, Non-Insulin-Dependent

United States
Hoffmann-La Roche

Completed

A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Alone

Diabetes Mellitus Type 2

United States, Mexico, Argentina
Hoffmann-La Roche

Completed

A Pharmacokinetics Study of Aleglitazar in Combination With Digoxin in Healthy Volunteers

Healthy Volunteer

United Kingdom
Hoffmann-La Roche

Completed

A Pharmacodynamic/Pharmacokinetic Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus on Treatment With Lisinopril

Diabetes Mellitus Type 2

United States
Hoffmann-La Roche

Completed

A Study of Aleglitazar in Combination With Ibuprofen in Healthy Volunteers

Healthy Volunteer

United States
Hoffmann-La Roche

Completed

A Study of Aleglitazar in Combination With Aspirin in Healthy Volunteers

Healthy Volunteer

United States
Hoffmann-La Roche

Completed

A Study of Aleglitazar in Combination With Oral Contraceptive Healthy Volunteers

Healthy Volunteer

United Kingdom
Hoffmann-La Roche

Completed

A Study to Investigate the Effects of Rifampicin on the Pharmacokinetics of Aleglitazar in Healthy Volunteers

Healthy Volunteer

United Kingdom

3

Subscribe